PAA Members
Member Login

Shingles (Herpes Zoster) Update for Healthcare Providers

Shingles (Herpes Zoster) Update for Healthcare Providers

Shingles vaccination is the only way to protect against shingles and postherpetic neuralgia (PHN), the most common complication from shingles. CDC recommends that healthy adults 50 years and older get two doses of SHINGRIX (recombinant zoster vaccine), separated by 2 to 6 months, to prevent shingles and the complications from the disease. Recombinant zoster vaccine (RZV, SHINGRIX ) has been in use since 2017 and is recommended by ACIP as the preferred shingles vaccine. GSK is continuing to steadily increase supply of SHINGRIX for the US market and anticipates producing and distributing more doses in 2020 than in 2019. They announced in June that as of 6/8/2020, SHINGRIX has been moved from “Backorder” status to “Available” on GSKDirect.
Log in to learn more. Not a member? Join now.